Abstract: Provided are compositions, kits, and methods for separating cells including complexes of at least one type of linker capable of binding to an antibody or antigen binding fragment and a solid phase.
Type:
Grant
Filed:
April 23, 2013
Date of Patent:
November 24, 2015
Assignee:
SAMSUNG ELECTRONICS CO., LTD.
Inventors:
Kyung-yeon Han, Yeon-jeong Kim, Jong-myeon Park, Chang-eun Yoo
Abstract: The present invention relates to a system, device, and method for the high throughput multiplexed detection of a wide number of compounds. The invention comprises of a microwell array coupled to a capture agent array to form a plurality of interfaces between a microwell and a set of immobilized capture agents. The set of capture agents comprises a plurality of distinguishable features, with each feature corresponding to the detection of a particular compound of interest. In certain embodiments, each microwell is configured to contain a single cell. The invention is therefore capable of performing a high throughput analysis of single cell profiles, including profiles of secreted compounds.
Abstract: The invention relates to a method for detecting and measuring the presence of nucleosome-protein adducts and the use of such measurements for the detection and diagnosis of disease. The invention also relates to a method of identifying nucleosome adduct biomarkers for the detection and diagnosis of disease and to biomarkers identified by said method.
Type:
Grant
Filed:
December 7, 2012
Date of Patent:
November 17, 2015
Assignee:
Singapore Volition Pte. Limited
Inventors:
Jacob Vincent Micallef, Mark Edward Eccleston, Marielle Herzog
Abstract: The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.
Type:
Grant
Filed:
March 13, 2013
Date of Patent:
November 10, 2015
Assignees:
Singulex, Inc., The Regents of the University of California
Inventors:
Philippe Goix, Robert Puskas, John Todd, Richard Livingston, Douglas Held, Allan H. B. Wu
Abstract: The invention relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them. The reagents are preferably employed in proteomic analysis using mass spectrometry. The antibody reagents specifically bind to the remnant of ubiquitin (i.e., a diglycine modified epsilon amine of lysine) left on a peptide which as been generated by digesting or chemically treating ubiquitinated proteins. The inventive antibody reagents' affinity to the ubiquitin remnant does not depend on the remaining amino acid sequences flanking the modified (i.e., ubiquitinated) lysine, i.e., they are context independent.
Type:
Grant
Filed:
April 4, 2013
Date of Patent:
November 10, 2015
Assignee:
Cell Signaling Technology, Inc.
Inventors:
John Edward Rush, II, Jing Li, Ailan Guo
Abstract: A method for the detection of an early biomarker for assessing a change in renal status in a mammalian subject following a renal event. The method typically includes the steps of (a) providing a body fluid sample obtained from a mammalian subject; (b) analyzing the molecular weight of the proteins in the sample using proteome analysis; and (c) identifying the presence of a protein in the sample selected from the group consisting of a 6.4 kDa protein, a 28.5 kDa protein, a 33 kDa protein, a 44 kDa protein, a 67 kDa protein, and combinations thereof. The presence of one of these proteins can serve as an early biomarker for assessing a change in renal status. The levels of these proteins can be compared to predetermined levels, and thus provide a determination of the subject's renal status. The invention also includes a method of assessing the administration of aprotinin during cardio-pulmonary bypass surgery and provides for methods where the level of the 6.
Abstract: The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
Type:
Grant
Filed:
July 5, 2013
Date of Patent:
November 3, 2015
Assignee:
Pierre Fabre Medicament
Inventors:
Charlotte Beau-Larvor, Liliane Goetsch, Nicolas Boute
Abstract: Provided herein are methods and devices for the detection of conditions or disorders by detecting altered levels of stress response pathway biomarkers. Also provided are methods and reagents for identifying panels of biomarkers associated with a condition or disorder.
Abstract: The present invention relates to the use, in cosmetics and in therapeutics, of at least one antimicrobial protein belonging to the ribonuclease family, ribonuclease 7, or of polypeptides derived from said protein, notably as a marker for evaluating the condition of the epidermis. It further relates to the use of at least one polypeptide according to the invention, of at least one nucleic acid sequence coding for a polypeptide according to the invention, or of at least one agent that modulates the expression or the activity, notably biological, of said polypeptide or of its interaction with an element of the extracellular matrix, for the preparation of compositions intended for the prevention and/or treatment of skin disorders.
Type:
Grant
Filed:
November 16, 2007
Date of Patent:
November 3, 2015
Assignee:
L'OREAL
Inventors:
Mark Donovan, Dominique Bernard, Isabelle Castiel, Veronique Chaussade
Abstract: Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
October 13, 2015
Assignee:
Abbott Laboratories
Inventors:
Barry L. Dowell, Susan Gayda, Qiaoqiao Ruan, Joseph P. Skinner, Sergey Y. Tetin
Abstract: In the method of assaying an analyte in a sample of the present invention, magnetic silica particles are used. The magnetic silica particles include: silica particles containing 60 to 95% by weight of a superparamagnetic metal oxide that has an average particle size of 1 to 15 nm; and the analyte, an analog of the analyte, or a substance capable of specifically binding to the analyte immobilized on the surface of the silica particles.
Type:
Grant
Filed:
May 31, 2012
Date of Patent:
October 13, 2015
Assignees:
SANYO CHEMICAL INDUSTRIES, LTD., WAKO PURE CHEMICAL INDUSTRIES, LTD.
Inventors:
Yusuke Mizuno, Masamitsu Miyamori, Shinjiro Matsuda, Yo Yagura
Abstract: Kits and methods detect sucralose or determine sucralose concentration in a sample by using polyclonal or monoclonal anti-sucralose antibodies. An ELISA assay or other immunoassay detects sucralose or determines sucralose concentration in various samples.
Abstract: Method and test kit for quantitative determination of Vitamin D metabolites in blood, wherein a predetermined amount of blood is pre-analytically immobilized on a solid sorption material. Thereby, hemolysis of the blood has no effect on the analysis of vitamin D metabolites. For quantitative analysis the dried blood spot on the sorption material is dissolved with an aqueous solvent buffer containing detergent, pH 7.0 to 10.0, and the vitamin D metabolites are eluted with a protic organic solution having a permittivity of less than 35. The eluate is analyzed for vitamin D metabolites using conventional methods.
Type:
Grant
Filed:
April 4, 2012
Date of Patent:
September 22, 2015
Assignee:
Immundiagnostik AG
Inventors:
Franz P. Armbruster, Hans J. Gron, Claudia Schumann
Abstract: An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewisb and Lewisy antigens and derivatives thereof (e.g., a sialylated form of Lewis a, Lewis x, Lewis b, Lewis y; H-1, H-2, Lewis a, Lewis x, Lewis b or Lewis y).
Type:
Grant
Filed:
September 23, 2014
Date of Patent:
September 15, 2015
Assignees:
The General Hospital Corporation, Instituto Nacional de Ciencias Medicas Y Nutricion, Children's Hospital Medical Care
Inventors:
Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
Abstract: An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewisb and Lewisy antigens and derivatives thereof (e.g., a sialylated form of Lewis a, Lewis x, Lewis b, Lewis y; H-1, H-2, Lewis a, Lewis x, Lewis b or Lewis y).
Type:
Grant
Filed:
October 2, 2013
Date of Patent:
September 15, 2015
Assignees:
The General Hospital Corporation, Instituto Nacional de Ciencias Medicas Y Nutricion, Children's Hospital Medical Center
Inventors:
Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
Abstract: The invention relates to a method for the determination of the time from onset of atrial fibrillation to presentation in a patient comprising the steps of: providing a sample of a bodily fluid of said patient, determining the level of proANP (SEQ ID NO: 1) or fragments thereof in said sample, correlating the level of proANP or fragments thereof to the time from the onset of atrial fibrillation to presentation of said patient, wherein said fragments have a length of at least 6 amino acid residues.
Abstract: An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein ASC in said sample in vitro.
Type:
Grant
Filed:
September 10, 2013
Date of Patent:
August 25, 2015
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Herbert Andres, Johann Karl, Julia Riedlinger
Abstract: A system and method for analyzing a sample of liquid having an NMR signal in response to a magnetic field for the presence of an analyte. Included is an NMR device having a testing section that is adapted to contain a liquid and apply a magnetic field to the liquid. A complex comprised of a conjugate having a field gradient bound to the analyte that is of sufficient magnitude to quench the NMR signal of the liquid when in the test section whereby the presence of the complex is determined by the absence of the NMR signal.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
August 18, 2015
Assignee:
The Regents of the University of New Mexico
Abstract: A system and method for analyzing a sample of liquid having an NMR signal in response to a magnetic field for the presence of an analyte. Included is an NMR device having a testing section that is adapted to contain a liquid and apply a magnetic field to the liquid. A complex comprised of a conjugate having a field gradient bound to the analyte that is of sufficient magnitude to quench the NMR signal of the liquid when in the test section whereby the presence of the complex is determined by the absence of the NMR signal. The system and method also include a container having a binding agent therein that has an affinity for the analyte or foreign agent that is used to remove the foreign agent from a patient's blood or plasma. Blood or plasma is shunted through the container to remove or reduce the foreign agent by extracorporeal circulation.
Type:
Grant
Filed:
June 6, 2014
Date of Patent:
August 18, 2015
Assignee:
The Regents of the University of New Mexico